Programmed death-ligand 1 (PD-L1) polymorphisms as predictive biomarkers for the development of liver cirrhosis and hepatocellular carcinoma in HCV Egyptian patients
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed death-ligand 1 (PD-L1) polymorphisms as predictive biomarkers for the development of liver cirrhosis and hepatocellular carcinoma in HCV Egyptian patients
Authors
Keywords
-
Journal
Tumour Virus Research
Volume 14, Issue -, Pages 200249
Publisher
Elsevier BV
Online
2022-10-18
DOI
10.1016/j.tvr.2022.200249
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
- (2021) Kyoko Oura et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Programmed cell death ligand‐1: A dynamic immune checkpoint in cancer therapy
- (2020) Muhammad Kalim et al. Chemical Biology & Drug Design
- Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
- (2020) Amblessed E. Onuma et al. GENE EXPRESSION
- Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
- (2019) Gao-Min Liu et al. Cancer Cell International
- The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
- (2019) Günther Schönrich et al. Frontiers in Cellular and Infection Microbiology
- Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
- (2019) Xiangfeng Shen et al. Frontiers in Immunology
- Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies
- (2019) Mohammad Hashemi et al. Cancers
- Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer
- (2018) Dan Tan et al. Cancer Biomarkers
- Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population
- (2018) Qigui Xie et al. GENE
- Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer
- (2018) Yanhua Wu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis
- (2018) Ju Zou et al. PATHOLOGY RESEARCH AND PRACTICE
- Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
- (2018) Chenyue Qian et al. Journal of Diabetes Research
- Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer
- (2017) Shin Yup Lee et al. GENE
- Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma
- (2017) Min-Kyung Yeo et al. HUMAN PATHOLOGY
- Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility
- (2017) Rania H. Khalifa et al. JOURNAL OF MEDICAL VIROLOGY
- Variant SNPs at the microRNA complementary site in the B7-H1 3′-untranslated region increase the risk of non-small cell lung cancer
- (2017) Wenwen Du et al. Molecular Medicine Reports
- Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
- (2017) Takashi Nomizo et al. Scientific Reports
- A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
- (2013) Weipeng Wang et al. HUMAN GENETICS
- Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis
- (2012) Pierre Nahon et al. JOURNAL OF HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started